Skip to main content
Top
Published in: European Journal of Pediatrics 10/2013

01-10-2013 | Original Article

Ophthalmological assessment of children with neurofibromatosis type 1

Authors: Catherine Cassiman, Eric Legius, Werner Spileers, Ingele Casteels

Published in: European Journal of Pediatrics | Issue 10/2013

Login to get access

Abstract

Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder, caused by mutations in the NF1 gene, located on chromosome band 17q11.2. In 1988, the National Institutes of Health created specific criteria for the diagnosis of NF1. Four cardinal criteria are assessed through ophthalmological screening: Lisch nodules, optic pathway glioma, a distinctive osseous lesion (sphenoid dysplasia), and the (orbital) plexiform neurofibroma. NF1 patients are prone to the development of central and peripheral nervous system tumors. Especially young children are at risk for growing optic pathway gliomas that can threaten their sight. From an early age, children with NF1 undergo regular ophthalmological examinations. Little is known about the natural progress of these clinical features and the guidelines for screening and follow-up are controversial. Several questions remain unanswered. Conclusion: Most of these questions could be solved by better understanding of the natural history of optic pathway gliomas. There is a tendency towards using vision as a primary objective in clinical treatment trials; this way we can evaluate new treatment strategies and focus specifically on visual evolution so we will be able to select even more carefully which patient would benefit treatment. For future clinical trials, a standardized visual acuity assessment protocol is therefore mandatory.
Literature
1.
go back to reference Avery RA, Ferner RE, Listernick R, Fisher MJ, Gutmann DH, Liu GT (2012) Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research. J Neurooncol 110:1–7PubMedCrossRef Avery RA, Ferner RE, Listernick R, Fisher MJ, Gutmann DH, Liu GT (2012) Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research. J Neurooncol 110:1–7PubMedCrossRef
3.
go back to reference Avery RA, Liu GT, Fisher MJ, Quinn GE, Belasco JB, Phillips PC, Maguire MG, Balcer LJ (2011) Retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol 151:542–549PubMedCrossRef Avery RA, Liu GT, Fisher MJ, Quinn GE, Belasco JB, Phillips PC, Maguire MG, Balcer LJ (2011) Retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol 151:542–549PubMedCrossRef
4.
go back to reference Binning MJ, Liu JK, Kestle JR, Brockmeyer DL, Walker ML (2007) Optic pathway gliomas: a review. Neurosurg Focus 23(5):E2PubMedCrossRef Binning MJ, Liu JK, Kestle JR, Brockmeyer DL, Walker ML (2007) Optic pathway gliomas: a review. Neurosurg Focus 23(5):E2PubMedCrossRef
5.
go back to reference Boley S, Sloan JL, Pemov A, Stewart DR (2009) A quantitative assessment of the burden and distribution of Lisch nodules in adults with neurofibromatosis type 1. Invest Ophthal Vis Sci 50:5035–5043PubMedCrossRef Boley S, Sloan JL, Pemov A, Stewart DR (2009) A quantitative assessment of the burden and distribution of Lisch nodules in adults with neurofibromatosis type 1. Invest Ophthal Vis Sci 50:5035–5043PubMedCrossRef
6.
go back to reference Brems H, Beert E, de Ravel T, Legius E (2009) Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol 10:508–515PubMedCrossRef Brems H, Beert E, de Ravel T, Legius E (2009) Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol 10:508–515PubMedCrossRef
7.
go back to reference Brems H, Pasmant E, Van Minkelen R, Wimmer K, Upadhyaya M, Legius E, Messiaen L (2012) Review and update of SPRED1 mutations causing Legius syndrome. Hum Mutat 33:1538–1546PubMedCrossRef Brems H, Pasmant E, Van Minkelen R, Wimmer K, Upadhyaya M, Legius E, Messiaen L (2012) Review and update of SPRED1 mutations causing Legius syndrome. Hum Mutat 33:1538–1546PubMedCrossRef
8.
go back to reference Chang L, El-Dairi MA, Frempong TA, Burner EL, Bhatti MT, Young TL, Leigh F (2010) Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas. J AAPOS 14:511–517PubMedCrossRef Chang L, El-Dairi MA, Frempong TA, Burner EL, Bhatti MT, Young TL, Leigh F (2010) Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas. J AAPOS 14:511–517PubMedCrossRef
9.
go back to reference De Keyser C, Maudgal P, Legius E, Van Ginderdeuren R, Casteels I (2011) Juvenile xanthogranuloma of the corneoscleral limbus: report of two cases. Ophthal Genet 32:54–56PubMedCrossRef De Keyser C, Maudgal P, Legius E, Van Ginderdeuren R, Casteels I (2011) Juvenile xanthogranuloma of the corneoscleral limbus: report of two cases. Ophthal Genet 32:54–56PubMedCrossRef
10.
go back to reference Dobson V, Quinn GE, Siatkowski RM, Baker JD, Hardy RJ, Reynolds JD, Trese MT, Tung B (1999) Agreement between grating acuity at age 1 year and Snellen acuity at age 5.5 years in the preterm child. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Invest Ophthalmol Vis Sci 40:496–503PubMed Dobson V, Quinn GE, Siatkowski RM, Baker JD, Hardy RJ, Reynolds JD, Trese MT, Tung B (1999) Agreement between grating acuity at age 1 year and Snellen acuity at age 5.5 years in the preterm child. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Invest Ophthalmol Vis Sci 40:496–503PubMed
11.
go back to reference Dobson V, Quinn GE, Tung B, Palmer EA, Reynolds JD (1995) Comparison of recognition and grating acuities in very-low-birth-weight children with and without retinal residua of retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Invest Ophthalmol Vis Sci 36:692–702PubMed Dobson V, Quinn GE, Tung B, Palmer EA, Reynolds JD (1995) Comparison of recognition and grating acuities in very-low-birth-weight children with and without retinal residua of retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Invest Ophthalmol Vis Sci 36:692–702PubMed
12.
go back to reference Drover JR, Felius J, Cheng CS, Morale SE, Wyatt L, Birch EE (2008) Normative pediatric visual acuity using single surrounded HOTV optotypes on the electronic visual acuity tester following the amblyopia treatment study protocol. J AAPOS 12:145–149PubMedCrossRef Drover JR, Felius J, Cheng CS, Morale SE, Wyatt L, Birch EE (2008) Normative pediatric visual acuity using single surrounded HOTV optotypes on the electronic visual acuity tester following the amblyopia treatment study protocol. J AAPOS 12:145–149PubMedCrossRef
13.
go back to reference Erb MH, Uzcategui N, See RF, Burnstine MA (2007) Orbitotemporal neurofibromatosis: classification and treatment. Orbit 26:223–228PubMedCrossRef Erb MH, Uzcategui N, See RF, Burnstine MA (2007) Orbitotemporal neurofibromatosis: classification and treatment. Orbit 26:223–228PubMedCrossRef
14.
go back to reference Ferraz-Filho JR, da Rocha AJ, Muniz MP, Souza AS, Goloni-Bertollo EM, Pavarino-Bertelli EC (2011) Diffusion tensor MR imaging in neurofibromatosis type 1: expanding the knowledge of microstructural brain abnormalities. Pediatr Radiol 42:449–454PubMedCrossRef Ferraz-Filho JR, da Rocha AJ, Muniz MP, Souza AS, Goloni-Bertollo EM, Pavarino-Bertelli EC (2011) Diffusion tensor MR imaging in neurofibromatosis type 1: expanding the knowledge of microstructural brain abnormalities. Pediatr Radiol 42:449–454PubMedCrossRef
15.
go back to reference Filippi CG, Bos A, Nickerson JP, Salmela MB, Koski CJ, Cauley KA (2012) Magnetic resonance diffusion tensor imaging (MRDTI) of the optic nerve and optic radiations at 3T in children with neurofibromatosis type I (NF-1). Pediatr Radiol 42:168–174PubMedCrossRef Filippi CG, Bos A, Nickerson JP, Salmela MB, Koski CJ, Cauley KA (2012) Magnetic resonance diffusion tensor imaging (MRDTI) of the optic nerve and optic radiations at 3T in children with neurofibromatosis type I (NF-1). Pediatr Radiol 42:168–174PubMedCrossRef
16.
go back to reference Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu GT (2012) Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol 14:790–797PubMedCrossRef Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu GT (2012) Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol 14:790–797PubMedCrossRef
17.
go back to reference Holder GE, Gale RP, Acheson JF, Robson AG (2009) Electrodiagnostic assessment in optic nerve disease. Curr Opin Neurol 22:3–10PubMedCrossRef Holder GE, Gale RP, Acheson JF, Robson AG (2009) Electrodiagnostic assessment in optic nerve disease. Curr Opin Neurol 22:3–10PubMedCrossRef
18.
go back to reference Iannaccone A, McCluney RA, Brewer VR, Spiegel PH, Taylor JS, Kerr NC, Pivnick EK (2002) Visual evoked potentials in children with neurofibromatosis type 1. Doc Ophthalmol 105:63–81PubMedCrossRef Iannaccone A, McCluney RA, Brewer VR, Spiegel PH, Taylor JS, Kerr NC, Pivnick EK (2002) Visual evoked potentials in children with neurofibromatosis type 1. Doc Ophthalmol 105:63–81PubMedCrossRef
19.
go back to reference Jouhilahti EM, Peltonen S, Heape AM, Peltonen J (2011) The pathoetiology of neurofibromatosis 1. Am J Pathol 178:1932–1939PubMedCrossRef Jouhilahti EM, Peltonen S, Heape AM, Peltonen J (2011) The pathoetiology of neurofibromatosis 1. Am J Pathol 178:1932–1939PubMedCrossRef
20.
go back to reference Kantaputra PN, van den Ouweland A, Sangruchi T, Limwongse C (2012) Neurofibromatosis, type 1 with underdeveloped eyes and a novel NF1 mutation. Am J Med Genet A 158A:1750–1753PubMedCrossRef Kantaputra PN, van den Ouweland A, Sangruchi T, Limwongse C (2012) Neurofibromatosis, type 1 with underdeveloped eyes and a novel NF1 mutation. Am J Med Genet A 158A:1750–1753PubMedCrossRef
21.
go back to reference Kelly JP, Leary S, Khanna P, Weiss AH (2012) Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas. Ophthalmology 119:1231–1237PubMedCrossRef Kelly JP, Leary S, Khanna P, Weiss AH (2012) Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas. Ophthalmology 119:1231–1237PubMedCrossRef
22.
go back to reference Kelly JP, Weiss AH (2006) Comparison of pattern visual-evoked potentials to perimetry in the detection of visual loss in children with optic pathway gliomas. J AAPOS 10:298–306PubMedCrossRef Kelly JP, Weiss AH (2006) Comparison of pattern visual-evoked potentials to perimetry in the detection of visual loss in children with optic pathway gliomas. J AAPOS 10:298–306PubMedCrossRef
23.
go back to reference Lee V, Ragge NK, Collin JR (2004) Orbitotemporal neurofibromatosis. Clinical features and surgical management. Ophthalmology 111:382–388PubMedCrossRef Lee V, Ragge NK, Collin JR (2004) Orbitotemporal neurofibromatosis. Clinical features and surgical management. Ophthalmology 111:382–388PubMedCrossRef
24.
go back to reference Legius E, Wu R, Eyssen M, Marynen P, Fryns JP, Cassiman JJ (1995) Encephalocraniocutaneous lipomatosis with a mutation in the NF1 gene. J Med Genet 32:316–319PubMedCrossRef Legius E, Wu R, Eyssen M, Marynen P, Fryns JP, Cassiman JJ (1995) Encephalocraniocutaneous lipomatosis with a mutation in the NF1 gene. J Med Genet 32:316–319PubMedCrossRef
25.
go back to reference Listernick R, Charrow J, Gutmann DH (2001) Comments on neurofibromatosis 1 and optic pathway tumors. Am J Med Genet 102:105PubMedCrossRef Listernick R, Charrow J, Gutmann DH (2001) Comments on neurofibromatosis 1 and optic pathway tumors. Am J Med Genet 102:105PubMedCrossRef
26.
go back to reference Listernick R, Ferner RE, Liu GT, Gutmann DH (2007) Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 61:189–198PubMedCrossRef Listernick R, Ferner RE, Liu GT, Gutmann DH (2007) Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 61:189–198PubMedCrossRef
27.
go back to reference Listernick R, Louis DN, Packer RJ, Gutmann DH (1997) Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 41:143–149PubMedCrossRef Listernick R, Louis DN, Packer RJ, Gutmann DH (1997) Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 41:143–149PubMedCrossRef
28.
29.
go back to reference Liu GT, Brodsky MC, Phillips PC, Belasco J, Janss A, Golden JC, Bilaniuk LL, Burson GT, Duhaime AC, Sutton LN (2004) Optic radiation involvement in optic pathway gliomas in neurofibromatosis. Am J Ophthalmol 137:407–414PubMedCrossRef Liu GT, Brodsky MC, Phillips PC, Belasco J, Janss A, Golden JC, Bilaniuk LL, Burson GT, Duhaime AC, Sutton LN (2004) Optic radiation involvement in optic pathway gliomas in neurofibromatosis. Am J Ophthalmol 137:407–414PubMedCrossRef
30.
go back to reference Lober RM, Guzman R, Cheshier SH, Fredrick DR, Edwards MS, Yeom KW (2012) Application of diffusion tensor tractography in pediatric optic pathway glioma. J Neurosurg Pediatr 10:273–280PubMedCrossRef Lober RM, Guzman R, Cheshier SH, Fredrick DR, Edwards MS, Yeom KW (2012) Application of diffusion tensor tractography in pediatric optic pathway glioma. J Neurosurg Pediatr 10:273–280PubMedCrossRef
31.
go back to reference Nguyen R, Dombi E, Widemann BC, Solomon J, Fuensterer C, Kluwe L, Friedman JM, Mautner VF (2012) Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis 7:75PubMedCrossRef Nguyen R, Dombi E, Widemann BC, Solomon J, Fuensterer C, Kluwe L, Friedman JM, Mautner VF (2012) Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis 7:75PubMedCrossRef
32.
go back to reference Nguyen R, Kluwe L, Fuensterer C, Kentsch M, Friedrich RE, Mautner VF (2011) Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits. J Pediatr 159:652–655PubMedCrossRef Nguyen R, Kluwe L, Fuensterer C, Kentsch M, Friedrich RE, Mautner VF (2011) Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits. J Pediatr 159:652–655PubMedCrossRef
33.
go back to reference Nichols JC, Amato JE, Chung SM (2003) Characteristics of Lisch nodules in patients with neurofibromatosis type 1. JPOS 40:293–296 Nichols JC, Amato JE, Chung SM (2003) Characteristics of Lisch nodules in patients with neurofibromatosis type 1. JPOS 40:293–296
34.
go back to reference Parsa CF, Givrad S (2008) Pilocytic astrocytomas as hamartomas: implications for treatment. Br J Ophthalmol 92:3–6PubMedCrossRef Parsa CF, Givrad S (2008) Pilocytic astrocytomas as hamartomas: implications for treatment. Br J Ophthalmol 92:3–6PubMedCrossRef
35.
go back to reference Pilling RF, Taylor RH (2010) Screening children with NF1 for optic pathway glioma–No. Eye (Lond) 24:1432–1434CrossRef Pilling RF, Taylor RH (2010) Screening children with NF1 for optic pathway glioma–No. Eye (Lond) 24:1432–1434CrossRef
36.
go back to reference Ragge NK, Falk RE, Cohen WE, Murphree AL (1993) Images of Lisch nodules across the spectrum. Eye (Lond) 7:95–101CrossRef Ragge NK, Falk RE, Cohen WE, Murphree AL (1993) Images of Lisch nodules across the spectrum. Eye (Lond) 7:95–101CrossRef
37.
go back to reference Segal L, Darvish-Zargar M, Dilenge ME, Ortenberg J, Polomeno RC (2010) Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. J AAPOS 14:155–158PubMedCrossRef Segal L, Darvish-Zargar M, Dilenge ME, Ortenberg J, Polomeno RC (2010) Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. J AAPOS 14:155–158PubMedCrossRef
38.
go back to reference Shah KN (2010) The diagnostic and clinical significance of café-au-lait macules. Pediatr Clin North Am 57:1131–1153PubMedCrossRef Shah KN (2010) The diagnostic and clinical significance of café-au-lait macules. Pediatr Clin North Am 57:1131–1153PubMedCrossRef
39.
go back to reference Shamji MF, Benoit BG (2007) Syndromic and sporadic pediatric optic pathway gliomas: review of clinical and histopathological differences and treatment implications. Neurosurg Focus 23:E3PubMedCrossRef Shamji MF, Benoit BG (2007) Syndromic and sporadic pediatric optic pathway gliomas: review of clinical and histopathological differences and treatment implications. Neurosurg Focus 23:E3PubMedCrossRef
40.
go back to reference Siatkowski RM (2006) VEP testing and visual pathway gliomas: not quite ready for prime time. J AAPOS 10:293–295PubMedCrossRef Siatkowski RM (2006) VEP testing and visual pathway gliomas: not quite ready for prime time. J AAPOS 10:293–295PubMedCrossRef
41.
go back to reference Simmons I, Gogi D (2010) Screening children with NF1 for optic pathway glioma–Yes. Eye (Lond) 24:1429–1431CrossRef Simmons I, Gogi D (2010) Screening children with NF1 for optic pathway glioma–Yes. Eye (Lond) 24:1429–1431CrossRef
42.
go back to reference Sylvester CL, Drohan LA, Sergott RC (2006) Optic-nerve gliomas, chiasmal gliomas and neurofibromatosis type 1. Curr Opin Ophthalmol 17:7–11PubMedCrossRef Sylvester CL, Drohan LA, Sergott RC (2006) Optic-nerve gliomas, chiasmal gliomas and neurofibromatosis type 1. Curr Opin Ophthalmol 17:7–11PubMedCrossRef
43.
go back to reference Thiagalingam S, Flaherty M, Billson F, North K (2004) Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 111:568–577PubMedCrossRef Thiagalingam S, Flaherty M, Billson F, North K (2004) Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 111:568–577PubMedCrossRef
44.
go back to reference Williamson TH, Garner A, Moore AT (1991) Structure of Lisch nodules in neurofibromatosis type 1. Ophthal Paediatr Genet 12:11–17CrossRef Williamson TH, Garner A, Moore AT (1991) Structure of Lisch nodules in neurofibromatosis type 1. Ophthal Paediatr Genet 12:11–17CrossRef
45.
go back to reference Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL (2009) Neurofibromatosis type 1 revisited. Pediatrics 123:124–133PubMedCrossRef Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL (2009) Neurofibromatosis type 1 revisited. Pediatrics 123:124–133PubMedCrossRef
46.
go back to reference Wolsey DH, Larson SA, Creel D, Hoffman R (2006) Can screening for optic nerve gliomas in patients with neurofibromatosis type I be performed with visual-evoked potential testing? J AAPOS 10:307–311PubMedCrossRef Wolsey DH, Larson SA, Creel D, Hoffman R (2006) Can screening for optic nerve gliomas in patients with neurofibromatosis type I be performed with visual-evoked potential testing? J AAPOS 10:307–311PubMedCrossRef
47.
go back to reference Yerdelen D, Koc F, Durdu M, Karakas J (2011) Electrophysiological findings in neurofibromatosis type 1. Neurol Sci 306:42–48CrossRef Yerdelen D, Koc F, Durdu M, Karakas J (2011) Electrophysiological findings in neurofibromatosis type 1. Neurol Sci 306:42–48CrossRef
Metadata
Title
Ophthalmological assessment of children with neurofibromatosis type 1
Authors
Catherine Cassiman
Eric Legius
Werner Spileers
Ingele Casteels
Publication date
01-10-2013
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Pediatrics / Issue 10/2013
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-013-2035-2

Other articles of this Issue 10/2013

European Journal of Pediatrics 10/2013 Go to the issue